Apnimed Will Present Sleep Apnea Data in Phoenix
The company will showcase five new abstracts during the CHEST 2026 meeting held October 18-21.
Updated on Oct. 12, 2026 in Asthma
Live Poll
Would you prefer an oral pill over devices or surgery for treating sleep apnea?
Apnimed will share findings from its Phase 3 program and real-world sleep apnea research at the American College of Chest Physicians CHEST 2026 Annual Meeting in Phoenix, Arizona. The presentations will take place between October 18 and October 21, 2026.
Why it matters
This presentation allows the company to share new clinical evidence and explore novel paradigms for advancing obstructive sleep apnea patient management. The data comes ahead of a crucial regulatory milestone for the company's investigational oral therapy.
Apnimed is presenting five abstracts at the meeting, including three featuring AD109, an investigational drug composed of 2.3 mg of aroxybutynin and 75 mg of atomoxetine.
The players
Apnimed
A clinical-stage company based in Cambridge, Massachusetts, focused on developing oral therapies for sleep-related breathing diseases.
American College of Chest Physicians
The professional medical organization that hosts the annual CHEST meeting for pulmonary, critical care, and sleep medicine clinicians.
The details
The presentations at the Phoenix Convention Center will include rapid-fire oral sessions and poster displays to showcase clinical and real-world evidence. Apnimed will further engage attendees through a panel discussion and a sponsored learning theater.
Timeline
The CHEST 2026 Annual Meeting takes place in Phoenix from October 18-21, 2026.
Late-breaking and real-world data presentations are scheduled for October 20, 2026.
The Apnimed-sponsored learning theater presentation occurs on October 21, 2026.
The FDA has assigned a PDUFA goal date of February 28, 2027, for the AD109 application.
The Big Picture
This research follows the established trajectory of the AD109 Phase 3 clinical program. The presentations extend the public disclosure of findings previously generated by this study.
The potential approval of AD109 may offer a new oral treatment option for people with obstructive sleep apnea who require improved oxygenation. These clinical updates provide insight into how future treatment routines could be modified if the therapy receives regulatory clearance.
The takeaway
These presentations mark a significant step toward potential new standards of care for obstructive sleep apnea. Patients and providers should look for further updates following the FDA's decision in early 2027.
Further reading
For more on respiratory health developments, visit the Asthma section.
Source note: This article includes information reported by The Manila times.
Live Poll
Would you prefer an oral pill over devices or surgery for treating sleep apnea?
